Эффективность и безопасность тадалафила при лечении эректильной дисфункции

1. Рафальский В.В. Подходы к рациональному выбору ингибиторов фосфодиэстеразы 5 типа. Фарматека. 2004; 19–20: 1–8.
2. Baxendale RW, Burslem F, Phillips SC. Phosphodiesterase type 11 (PDE11) cellular localisation: progress towards defining a physiological role in testis and/or reproduction. J Urol 2001; suppl. 165: 340; abstr 1395.
3. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction: Results of the 'Cologne Male Survey. Int J Impot Res 2000; 12: 305–11.
4. Brock G. Oral agents: First-line therapy for erectile dysfunction. Eur Urol 2002; suppl. 1: 12–8.
5. Brock G, McMahon C, Chen K et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol (Baltimore) 2002; 168 (4, pt 1): 1332–6.
6. Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002; 56 (4): 300–4.
7. Eardley IV, Mirone F, Montorsi D et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. Sexual Medicine 2005; 96: 1323–32.
8. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J 2002; 4 (Suppl. H): H32–47.
9. Forgue ST, Patterson BE, Bedding AW et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006; 61 (3): 280–8.
10. Giuliano F, Varfnese L. Tadalafil: a novel treatment for erectile dysfunction. Eur Heart J Suppl 2002; 4 (suppl. H): H24–H31.
11. Guay AT. Erectile Dysfunction – Endothelial Dysfunction. Endocrinol Metab Clin N Am 2007; 36: 453–63.
12. Hickey K, Bokhari S, Shahzad A et al. Tadalafil does not alter coronary perfusion at rest or after pharmacological stress in subjects with coronary artery disease. Eur Heart J 2003; 24 (Abstr. Suppl.): 563.
13. Jackson G, Kloner RA, Costigan TM et al. Emmick Update on the clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 2004; 1: 157–63.
14. Kloner R, Mitchell M, Bedding A, Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J Urol (Baltimore) 2002; 167 (4): 176–7, abstr. 708.
15. Kloner RA, Jackson G, Hutter AM et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006; 97: 1778–84.
16. Lee J, Pommerville P, Brock G et al. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian «Treatment of Erectile Dysfunction» observational study. BJU International 2006; 98: 623–9.
17. Moncada I, Chan M, Damber J-E, Varanese L. Sexual intercourse attempts pattern in men with erectile dysfunction taking Tadalafil 3 times per week versus on demand: Results form the SURE. Int J Impot Res 2003; 15 (Suppl. 6): 2–4.
18. Patterson B, Bedding A, Jewell H et al. The effect of intrinsic and extrising factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 2001; 13 (Suppl. 5): S62, abstr. 16.
19. Ponholzer A, Temml C, Mock K et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005; 47: 80–6.
20. Sáenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of Tadalafil on erectile dysfunction in men with diabetes. Diabet Care 2002; 25: 2159–64.
21. Shabsigh R, Burnett AL, Eardley I et al. Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials. BJU Int 2005; 96 (6): 857–63.
22. Stroberg P, Murphy A, Costigan T. Switching Patients with Erectile Dysfunction from Sildenafil Citrate to Tadalafil: Results of a European Multicenter, Open-Label Study of Patient Preference. Clin Ther 2003; 25 (11): 2724–37.
23. Watts GF, Chew KK, Stuckey BG. The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat Clin Pract Cardiovasc Med 2007; 4 (5): 263–73.
24. Young JM, Feldman RA, Auerbach SM et al. Tadalafil Improved Erectile Function at Twenty-Four and Thirty-Six Hours After Dosing in Men With Erectile Dysfunction: US Trial. J Androl 2005; 26: 310–8.